Amgen buying rights to Advaxis cancer treatment

By Staff Report  /  Tuesday, August 2nd, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen buying rights to Advaxis cancer treatment

Thousand Oaks-based biotech giant Amgen said it will buy the rights to develop and commercialize a cancer immunotherapy treatment Aug. 2. Under the agreement, Amgen will pay Princeton, N.J.-based Advaxis $40 million and buy $25 million worth of Advaxis common stock for the rights to develop and commercialize a preclinical cancer immunotherapy, which is designed Read More →